Biography

試験の準備方法-最新のCCRP資格問題対応試験-素晴らしいCCRP日本語資格取得

P.S. Fast2testがGoogle Driveで共有している無料かつ新しいCCRPダンプ：https://drive.google.com/open?id=1v74n-gPbQ_LQWydmYm214UCRTMuES36_

当社のCCRP学習ガイド資料は、高品質のおかげで多くのお客様に支持されています。ユーザーが認定試験に合格する必要があるときに開始し、CCRPの実際の質問を選択します。2回目または3回目のバックアップオプションはありません。 CCRP実践ガイドは、ユーザーがテストに迅速に合格できるようにするために使用される方法を調査することに専念しています。したがって、絶え間ない努力により、CCRPの実際の質問の合格率は98％〜100％です。

SOCRA CCRP 認定試験の出題範囲：

トピック
出題範囲

トピック 1

• Research Study Start-Up: This section of the exam measures the skills of Clinical Research Coordinators and covers the initial planning and setup of a clinical trial. It involves coordinating the development of the study protocol, ensuring it considers ethical guidelines and regulatory pathways like IND or IDE. It also includes creating essential study documents like informed consent forms and case report forms. The domain covers obtaining necessary approvals from stakeholders like the IRB and sponsor, selecting study sites, training staff, and ensuring the study's compliance with various laws. Additionally, it involves obtaining the research product and preparing all necessary tools and documentation for the study's commencement.|Research Study Implementation: This section of the exam measures the skills of Clinical Research Associates and covers the active management and execution of the clinical trial. It focuses on following the study protocol and standard operating procedures, managing the investigational product, and ensuring ongoing regulatory compliance. The domain includes identifying, documenting, and reporting any study anomalies such as adverse events or protocol deviations. It also involves managing subject recruitment, consent, and retention, as well as maintaining all study records and essential documents. Furthermore, it covers communicating with all study stakeholders and participating in study audits to ensure quality and adherence to regulations.

トピック 2

• Research Study Closure: This section of the exam measures the skills of Clinical Research Coordinators and covers the activities required to properly conclude a clinical trial. It involves participating in the study closeout visit to verify documentation and account for the investigational product. The domain also includes developing and submitting final closure reports to the IRB, study sponsor, regulatory authorities, and clinicaltrials.gov. Finally, it covers the procedures for archiving study records.

>> CCRP資格問題対応 <<

CCRP試験の準備方法｜実用的なCCRP資格問題対応試験｜ユニークなCertified Clinical Research Professional (CCRP)日本語資格取得

やってみて購入します。我々Fast2testはすべてのお客様に責任を持っています。我々はあなたにSOCRAのCCRP試験ソフトのデモを無料で提供しています。あなたは体験してから安心で購入できます。われわれはあなたが弊社のSOCRAのCCRP試験ソフトを購入して満足することに自信を持っています。利用してからあなたも弊社のSOCRAのCCRP試験ソフトに自信を持っています。あなたは自信満々にSOCRAのCCRP試験に参加することができます。

SOCRA Certified Clinical Research Professional (CCRP) 認定 CCRP 試験問題 (Q117-Q122):

質問 # 117
In accordance with the CFR and the ICH GCP Guideline, which of the following is directly responsible for submitting protocols and amendments to the IRB/IEC for review?

• A. The contract research organization
• B. The sponsor
• C. The investigator
• D. The Food and Drug Administration

正解：C

解説：
Theinvestigatorbears direct responsibility for ensuring IRB/IEC review and approval before initiating a study or implementing any amendments.
* ICH E6(R2) 4.4.1:"Before initiating a trial, the investigator/institution should have written and dated approval/favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, and any other written information to be provided to subjects."
* 21 CFR 312.66:"An investigator shall assure that an IRB that complies with the requirements... will be responsible for the initial and continuing review and approval of the proposed clinical study." While sponsors may provide protocol documents, the legal obligation to submit and maintain IRB/IEC approval rests with the investigator at each site. CROs act under sponsor delegation but cannot replace investigator accountability.
Thus, the correct answer isB (The investigator).
References:
ICH E6(R2), §4.4.1 (Investigator responsibilities).
21 CFR 312.66 (Investigator assurance of IRB oversight).

質問 # 118
The sponsor of a multi-institutional clinical trial provided a site with information regarding a newly identified unanticipated adverse event attributed to study drug administration. The site's investigator has a subject actively receiving this study drug. Which of the following is the site investigator's responsibility to the subject?

• A. To discontinue the subject's study drug
• B. To give the subject's contact information to the sponsor in order to allow the sponsor to contact the subject
• C. To provide the subject with information regarding the significant new findings
• D. To submit this safety update to the regulatory authority

正解：C

解説：
Investigators are obligated to inform subjects ofnew informationthat may affect their willingness to continue.
* ICH E6(R2) 4.8.2:"If new information becomes available that may be relevant to a subject's willingness to continue participation, the informed consent document should be revised, and the subject should be informed in a timely manner."
* 21 CFR 50.25(b)(5):Consent must include a statement that "significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided." Thus, the investigator mustcommunicate new risk information to the subject.
Discontinuation (A) may not be warranted unless medically indicated. Reporting to FDA (B) is the sponsor's role. Sharing subject contact with sponsor (D) would violate confidentiality.
Correct answer:C.
References:
ICH E6(R2), §4.8.2.
21 CFR 50.25(b)(5).

質問 # 119
In accordance with the CFR, a sponsor must submit a protocol amendment to the FDA for which of the following?

• A. The addition of a sub-investigator with the scientific training and expertise to conduct the investigation
• B. A change in the manufacturing site for the investigational product
• C. The addition of a new test that is intended to improve monitoring the subject for an adverse effect
• D. A significant change in an investigator's financial interest in the investigational product

正解：B

解説：
The U.S. Code of Federal Regulations (CFR) specifies when sponsors must notify FDA of changes to investigational drug studies under 21 CFR 312.30. A protocol amendment is required if there is:
A change to the protocol (e.g., objectives, design, subject population, dosing, or procedures).
The addition of a new investigator.
A change in the chemistry, manufacturing, or controls (CMC) that could significantly affect product quality or safety.
Among the listed options, a change in the manufacturing site (D) directly falls under significant manufacturing changes, requiring FDA submission. Changes in investigator financial interests (B) are covered under 21 CFR 54 and reported separately, not as protocol amendments. Addition of a sub-investigator (C) does not require a formal amendment, only site-level documentation and delegation log update. Addition of a monitoring test (A) may affect the protocol, but not necessarily mandate an amendment unless it changes objectives or subject safety endpoints.
Therefore, the correct answer is D. This ensures FDA oversight of product safety, efficacy, and compliance with CMC standards before investigational use.
References:
21 CFR 312.30 (Protocol amendments).
21 CFR 312.23(a)(7) (Chemistry, manufacturing, and controls information).

質問 # 120
A Phase I study of a new blood pressure medication has been submitted for initial approval to an IRB/IEC. In accordance with the CFR, the IRB/IEC must consider which of the following criteria when determining whether to approve the study?

• A. The funding source for the trial
• B. The equitability of the selection of subjects
• C. The availability of the patient population
• D. The educational background of the study team

正解：B

解説：
When reviewing protocols, IRBs/IECs are primarily responsible forsafeguarding human subjectsby evaluating risks, benefits, and fairness in subject selection.
* 21 CFR 56.111(a)(3):"In making its determination the IRB shall determine that... selection of subjects is equitable."
* 45 CFR 46.111(a)(3):Repeats this requirement, emphasizing fairness across gender, race, age, and socioeconomic status.
Other options:
* Patient population availability (A) is afeasibility issue, addressed by investigators and sponsors, not IRBs.
* Education of the study team (C) is confirmed by thesponsor and investigator, not IRB.
* Funding sources (D) may raise conflict of interest concerns, but they are not IRB approval criteria per federal regulations.
Thus, IRBs focus onjustice and fairness in subject selectionas part of the Belmont Report principles.
References:
21 CFR 56.111(a)(3).
Belmont Report (Justice principle).

質問 # 121
In accordance with the ICH GCP Guideline, which of the following should the investigator refer to when a subject returns unused medication at the completion of a study?

• A. The CRO/site agreements
• B. The sponsor's written procedures
• C. The Investigator's Brochure
• D. The investigational pharmacy's requirements

正解：B

解説：
Handling of investigational product (IP), including returns, is governed bysponsor's written procedures.
* ICH E6(R2) 4.6.3:"The investigator/institution should maintain records of the product's delivery, the inventory, the use by each subject, and the return to the sponsor or alternative disposition."
* ICH E6(R2) 5.13.3:"The sponsor should ensure that written procedures include instructions for... the return or alternative disposition of unused product(s)." The IB (A) describes pharmacology and safety, not IP logistics. CRO agreements (C) cover contractual duties, not product return processes. Local pharmacy policies (D) may apply operationally but do not override sponsor-required procedures.
Thus, the correct answer isB (The sponsor's written procedures).
References:
ICH E6(R2), §4.6.3 (Investigator product accountability).
ICH E6(R2), §5.13.3 (Sponsor product return procedures).

質問 # 122
......

まだSOCRAのCCRP認定試験を悩んでいますかこの情報の時代の中で専門なトレーニングを選択するのと思っていますか？良いターゲットのトレーニングを利用すれば有効で君のIT方面の大量の知識を補充 できます。SOCRAのCCRP認定試験「Certified Clinical Research Professional (CCRP)」によい準備ができて、試験に穏やかな心情をもって扱うことができます。Fast2testの専門家が研究された問題集を利用してください。

CCRP日本語資格取得: https://jp.fast2test.com/CCRP-premium-file.html

• CCRPリンクグローバル 🦼 CCRP日本語講座 🥔 CCRP日本語関連対策 🍷 ➽ CCRP 🢪を無料でダウンロード[ www.passtest.jp ]で検索するだけCCRP資格参考書
• CCRP試験関連情報 🦒 CCRP問題数 😇 CCRP受験準備 🎨 検索するだけで➥ www.goshiken.com 🡄から➽ CCRP 🢪を無料でダウンロードCCRP参考書内容
• CCRP問題数 🤝 CCRP受験準備 🤿 CCRP参考資料 🎤 ⏩ CCRP ⏪の試験問題は“ www.mogiexam.com ”で無料配信中CCRP参考資料
• CCRP試験関連情報 💲 CCRP参考資料 🏤 CCRP復習資料 📽 （ www.goshiken.com ）に移動し、⇛ CCRP ⇚を検索して、無料でダウンロード可能な試験資料を探しますCCRP最新日本語版参考書
• CCRP受験準備 🦃 CCRP資料勉強 🕝 CCRP入門知識 ℹ 今すぐ➡ www.xhs1991.com ️⬅️で⇛ CCRP ⇚を検索し、無料でダウンロードしてくださいCCRPテスト難易度
• CCRP日本語講座 🌉 CCRP入門知識 🛀 CCRP日本語関連対策 🍟 今すぐ➥ www.goshiken.com 🡄で➤ CCRP ⮘を検索して、無料でダウンロードしてくださいCCRP資格参考書
• CCRP専門知識内容 🛢 CCRP問題数 🕉 CCRP模擬試験問題集 🧁 時間限定無料で使える➤ CCRP ⮘の試験問題は➤ www.mogiexam.com ⮘サイトで検索CCRPウェブトレーニング
• CCRP試験勉強過去問 🤓 CCRP受験準備 🔗 CCRP更新版 🩲 今すぐ➠ www.goshiken.com 🠰で{ CCRP }を検索し、無料でダウンロードしてくださいCCRP更新版
• CCRP参考書内容 🧽 CCRP模擬試験問題集 🔕 CCRP試験勉強過去問 🔌 最新➡ CCRP ️⬅️問題集ファイルは{ www.topexam.jp }にて検索CCRP復習資料
• CCRP日本語関連対策 ➕ CCRPリンクグローバル ⏰ CCRPリンクグローバル 🐛 「 www.goshiken.com 」サイトで☀ CCRP ️☀️の最新問題が使えるCCRP資料勉強
• CCRP参考書内容 ⚔ CCRP問題数 🥕 CCRP参考資料 🔦 今すぐ⇛ www.goshiken.com ⇚を開き、➡ CCRP ️⬅️を検索して無料でダウンロードしてくださいCCRP日本語講座
• bookmarksparkle.com, socialevity.com, harleyqxgq236333.goabroadblog.com, prbookmarkingwebsites.com, bookmarkassist.com, compassionate.training, laytncatx290340.wikiannouncement.com, myatzsi213749.idblogmaker.com, ilovebookmarking.com, neilbmva877068.wikiworldstock.com, Disposable vapes

さらに、Fast2test CCRPダンプの一部が現在無料で提供されています：https://drive.google.com/open?id=1v74n-gPbQ_LQWydmYm214UCRTMuES36_